DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide

AIMS: In the initial 26-week, double-blind, double-dummy assessment period of the DURATION-2 trial in patients with Type 2 diabetes on metformin, the once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist exenatide once-weekly resulted in greater HbA(1c) improvement and weight reduction compar...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Wysham, C, Bergenstal, R, Malloy, J, Yan, P, Walsh, B, Malone, J, Taylor, K
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Publishing Ltd 2011
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3123706/
https://ncbi.nlm.nih.gov/pubmed/21434995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1464-5491.2011.03301.x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia